Qunming Dong

3.9k total citations · 1 hit paper
26 papers, 2.1k citations indexed

About

Qunming Dong is a scholar working on Pathology and Forensic Medicine, Epidemiology and Neurology. According to data from OpenAlex, Qunming Dong has authored 26 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 8 papers in Epidemiology and 5 papers in Neurology. Recurrent topics in Qunming Dong's work include Multiple Sclerosis Research Studies (10 papers), Substance Abuse Treatment and Outcomes (6 papers) and Neonatal Respiratory Health Research (4 papers). Qunming Dong is often cited by papers focused on Multiple Sclerosis Research Studies (10 papers), Substance Abuse Treatment and Outcomes (6 papers) and Neonatal Respiratory Health Research (4 papers). Qunming Dong collaborates with scholars based in United States, Switzerland and Australia. Qunming Dong's co-authors include Claudia L. Ordoñez, Steven M. Rowe, Michael W. Konstan, Bonnie W. Ramsey, Sally Rodriguez, J.S. Elborn, Karl Yen, Noel G. McElvaney, Richard B. Moss and Félix Ratjen and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Neurology.

In The Last Decade

Qunming Dong

26 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

2011 1.5k citations Bonnie W. Ramsey, Jane C. Davies et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Qunming Dong United States	11	1.5k	282	234	208	174	26	2.1k
Gary Layton United Kingdom	22	884 0.6×	283 1.0×	326 1.4×	428 2.1×	95 0.5×	44	1.9k
Xiaoling Zhang China	21	313 0.2×	261 0.9×	260 1.1×	104 0.5×	52 0.3×	110	1.5k
Ann M. Dnistrian United States	24	410 0.3×	97 0.3×	464 2.0×	150 0.7×	135 0.8×	44	1.9k
Andrew P. Feranchak United States	33	964 0.6×	243 0.9×	929 4.0×	207 1.0×	57 0.3×	53	2.8k
Tanja Gonska Canada	30	2.1k 1.4×	187 0.7×	485 2.1×	289 1.4×	57 0.3×	93	3.0k
David S. Rosenthal United States	26	508 0.3×	60 0.2×	162 0.7×	172 0.8×	470 2.7×	56	2.2k
Otwin Linderkamp Germany	27	714 0.5×	257 0.9×	706 3.0×	324 1.6×	47 0.3×	78	2.5k
Jung Ho Kim South Korea	20	309 0.2×	153 0.5×	335 1.4×	52 0.3×	83 0.5×	82	1.4k
Hong Wu China	23	301 0.2×	256 0.9×	484 2.1×	143 0.7×	72 0.4×	102	1.7k
Fade Mahmoud United States	20	193 0.1×	103 0.4×	403 1.7×	306 1.5×	77 0.4×	51	1.5k

Countries citing papers authored by Qunming Dong

Since Specialization

Citations

This map shows the geographic impact of Qunming Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qunming Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qunming Dong more than expected).

Fields of papers citing papers by Qunming Dong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qunming Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qunming Dong. The network helps show where Qunming Dong may publish in the future.

Co-authorship network of co-authors of Qunming Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Qunming Dong. A scholar is included among the top collaborators of Qunming Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qunming Dong. Qunming Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naismith, Robert T., Barry Hendin, Sibyl Wray, et al.. (2019). Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results. Multiple Sclerosis Journal - Experimental Translational and Clinical. 5(1). 2453242116–2453242116. 5 indexed citations

Coyle, Patricia K., et al.. (2018). Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week. Multiple Sclerosis and Related Disorders. 22. 134–138. 5 indexed citations

Corren, Jonathan, Mario Castro, Jorge Máspero, et al.. (2018). Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Ghent University Academic Bibliography (Ghent University). PA1124–PA1124. 10 indexed citations

Hendin, Barry, Robert T. Naismith, Sibyl Wray, et al.. (2018). Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks. Patient Preference and Adherence. Volume 12. 1289–1297. 4 indexed citations

Saida, Takahiko, et al.. (2017). Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis. Neurology and Therapy. 6(1). 153–159. 5 indexed citations

Giovannoni, Gavin, Deborah Steiner, Finn Sellebjerg, et al.. (2017). Sustained Disability Improvement as Assessed by a Multicomponent Endpoint in Secondary Progressive Multiple Sclerosis (SPMS) Patients: A Post Hoc Analysis from ASCEND (P5.359). Neurology. 88(16_supplement). 3 indexed citations

Kappos, Ludwig, Helmut Butzkueven, Heinz Wiendl, et al.. (2017). Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis Journal. 24(7). 963–973. 88 indexed citations

Butzkueven, Helmut, Ludwig Kappos, María Trojano, et al.. (2015). Disease Course in Multiple Sclerosis (MS) Patients Switching from Fingolimod to Natalizumab (P3.284). Neurology. 84(14_supplement). 1 indexed citations

Accurso, Frank J., Fredrick Van Goor, Jiuhong Zha, et al.. (2013). Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis. 13(2). 139–147. 111 indexed citations

10.

Rowe, Steven M., Bo Liu, Heather Hathorne, et al.. (2013). Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation. PLoS ONE. 8(7). e66955–e66955. 40 indexed citations

11.

Song, Tao, Qunming Dong, Abdul J. Sankoh, & Geert Molenberghs. (2013). Evaluation of Overall Treatment Effect in MMRM. Journal of Biopharmaceutical Statistics. 23(6). 1281–1293. 4 indexed citations

12.

Plant, Barry J., Bonnie W. Ramsey, Karl Yen, et al.. (2011). Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation. European Respiratory Journal. 38(Suppl 55). 4655–4655. 1 indexed citations

13.

Bigelow, George E., Kenzie L. Preston, John Schmittner, Qunming Dong, & David R. Gastfriend. (2011). Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose–effects and time-course. Drug and Alcohol Dependence. 123(1-3). 57–65. 38 indexed citations

14.

Ramsey, Bonnie W., Jane C. Davies, Noel G. McElvaney, et al.. (2011). A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. New England Journal of Medicine. 365(18). 1663–1672. 1528 indexed citations breakdown →

15.

Konstan, Michael W., Frank J. Accurso, Michael Boyle, et al.. (2010). Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D-CFTR Mutation Treated With VX-770, An Investigational Oral Potentiator Of CFTR. A2336–A2336. 2 indexed citations

16.

Ciraulo, Domenic A., Qunming Dong, Bernard L. Silverman, David R. Gastfriend, & Helen M. Pettinati. (2008). Early Treatment Response in Alcohol Dependence With Extended-Release Naltrexone. The Journal of Clinical Psychiatry. 69(2). 190–195. 21 indexed citations

17.

Pettinati, Helen M., David R. Gastfriend, Qunming Dong, Henry R. Kranzler, & Stephanie S. O’Malley. (2008). Effect of Extended‐Release Naltrexone (XR‐NTX) on Quality of Life in Alcohol‐Dependent Patients. Alcoholism Clinical and Experimental Research. 33(2). 350–356. 42 indexed citations

18.

O’Malley, Stephanie S., James C. Garbutt, David R. Gastfriend, Qunming Dong, & Henry R. Kranzler. (2007). Efficacy of Extended-Release Naltrexone in Alcohol-Dependent Patients Who Are Abstinent Before Treatment. Journal of Clinical Psychopharmacology. 27(5). 507–512. 93 indexed citations

19.

Dunbar, Joi, Ryan Z. Turncliff, Qunming Dong, et al.. (2006). Single‐ and Multiple‐Dose Pharmacokinetics of Long‐acting Injectable Naltrexone. Alcoholism Clinical and Experimental Research. 30(3). 480–490. 94 indexed citations

20.

Turncliff, Ryan Z., Joi Dunbar, Qunming Dong, et al.. (2005). Pharmacokinetics of Long‐Acting Naltrexone in Subjects With Mild to Moderate Hepatic Impairment. The Journal of Clinical Pharmacology. 45(11). 1259–1267. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact